MRI-measured regression of carotid atherosclerosis induced by statins with and without niacin in a randomised controlled trial: The NIA plaque study

Heart

Volumn 99, Issue 22, 2013, Pages 1675-1680

  Sibley, Christopher T ^a,b   Vavere, Andrea L ^b   Gottlieb, Ilan ^b   Cox, Christopher ^c   Matheson, Matthew ^c   Spooner, Amy ^b   Godoy, Gustavo ^b   Fernandes, Veronica ^b   Wasserman, Bruce A ^d   Bluemke, David A ^a,d   Lima, Joao A C ^b,d  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CHOLESTEROL; FLUINDOSTATIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

AGED; ARTERIAL WALL THICKNESS; ARTERIAL WALL VOLUME; ARTERY WALL; ARTICLE; ATHEROSCLEROTIC PLAQUE; BLOOD VESSEL PARAMETERS; CARDIOVASCULAR RISK; CAROTID ARTERIOGRAPHY; CAROTID ATHEROSCLEROSIS; CAROTID COIL; COMBINATION CHEMOTHERAPY; COMMON CAROTID ARTERY; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC IMAGING EQUIPMENT; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INTERNAL CAROTID ARTERY; LIPID CORE VOLUME; LIPOPROTEIN BLOOD LEVEL; LUMEN VOLUME; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

CORONARY ARTERY DISEASE; LIPIDS;

AGED; CAROTID ARTERY DISEASES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MAGNETIC RESONANCE IMAGING; MALE; NIACIN; PLAQUE, ATHEROSCLEROTIC; REMISSION INDUCTION;

EID: 84885866823     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2013-303926     Document Type: Article

References (30)

1. Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation 2010; 121:e46-215.
2. Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
3. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989;79:8-15.
4. Prospective Studies Collaboration. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55 000 vascular deaths. The Lancet 2007;370:1829-39.
5. Voight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. The Lancet 2012;380:572-80.
6. Azen SP, Mack WJ, Cashin-Hemphill L, et al. Progression of coronary artery disease predicts clinical coronary events: long-term follow-up from the cholesterol lowering atherosclerosis study. Circulation 1996;93:34-41. (Pubitemid 26006565)
7. Canner PL, Berge KG, Wenger NK. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986;8:1245-55. (Pubitemid 17208898)
8. Taylor AJ, Sullenberger LE, Lee HJ, et al. Arterial Biology for the Investigation of the Treatment Effects of Reducing cholesterol (ARBITER) 2: a double-blind, placebocontrolled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004;110:3512-17. (Pubitemid 39612564)
9. Brown BG, Zhao X-Q, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. NEJM 2001;345:1583-92. (Pubitemid 33126837)
10. Lee JMS, Robson MD, Yu L-M, et al. Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study. J Am Coll Cardiol 2009;54:1787-94.
11. Taylor AJ, Lee HJ, Sullenberger LE. The effect of 24 months of combination statin and extended-release niacin on carotid intimamedia thickness: ARBITER 3. Curr Med Res Opin 2006;22:2243-50. (Pubitemid 44789989)
12. HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J 2013;34:1279-91.
13. The AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011;365:2255-67.
14. Heart Protection Study Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo controlled trial. The Lancet 2002;360:7-22.
15. Zulman D, Sussman J, Chen X, et al. Examining the evidence: a systematic review of the inclusion and analysis of older adults in randomized controlled trials. J Gen Intern Med 2011;26:783-90.
16. Grundy SM, Becker D, Clark LT, et al. Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Circulation 2002;106:3143-421. (Pubitemid 36005324)
17. Wasserman BA, Smith WI, Trout Iii HH, et al. Carotid artery atherosclerosis: in vivo morphologic characterization with gadolinium-enhanced double-oblique MR imaging-initial results. Radiology 2002;223:566-73. (Pubitemid 34454344)
18. Wasserman BA, Sharrett AR, Lai S, et al. Risk factor associations with the presence of a lipid core in carotid plaque of asymptomatic individuals using high-resolution MRI: the Multi-Ethnic Study of Atherosclerosis (MESA). Stroke 2008;39:329-35. (Pubitemid 351619451)
19. Adame IM, Van Der Geest RJ, Wasserman BA, et al. Automatic segmentation and plaque characterization in atherosclerotic carotid artery MR images. Magn Reson Materi Phys Biol Med 2004;16:227-34. (Pubitemid 39193172)
20. Lima JA, Desai MY, Steen H, et al. Statin-induced cholesterol lowering and plaque regression after 6 months of magnetic resonance imaging-monitored therapy. Circulation 2004;110:2336-41. (Pubitemid 39407336)
21. Corti R, Fayad ZA, Fuster V, et al. Effects of lipid-lowering by simvastatin on human atherosclerotic lesions: a longitudinal study by high-resolution, noninvasive magnetic resonance imaging. Circulation 2001;104:249-52. (Pubitemid 32666942)
22. Michos ED, Sibley CT, Baer JT, et al. Niacin and statin combination therapy for atherosclerosis regression and prevention of cardiovascular disease events: reconciling the AIM-HIGH (atherothrombosis intervention in metabolic syndrome with low HDL/high triglycerides: impact on global health outcomes) trial with previous surrogate endpoint trials. J Am Coll Cardiol 2012;59:2058-64.
23. Taylor AJ, Villines TC, Stanek EJ, et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. NEJM 2009;361:2113-22.
24. Duivenvoorden R, de Groot E, Elsen BM, et al. In vivo quantification of carotid artery wall dimensions: 3.0-Tesla MRI versus B-mode ultrasound imaging. Circulation Cardiovasc Imaging 2009;2:235-42.
25. Stein JH, Douglas PS, Srinivasan SR, et al. Distribution and cross-sectional age-related increases of carotid artery intima-media thickness in young adults: The Bogalusa Heart Study. Stroke 2004;35:2782-87. (Pubitemid 39565171)
26. Polak JF, Pencina MJ, Pencina KM, et al. Carotid-wall intima-media thickness and cardiovascular events. N Engl J Med 2011;365:213-21.
27. Nicholls SJ. The AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome with low HDL/High Triglycerides: Impact on Global Health Outcomes) Trial: To Believe or Not to Believe? J Am Coll Cardiol 2012;59:2065-67.
28. Ray KK, Cannon CP, Cairns R, et al. Prognostic utility of ApoB/AI, total cholesterol/ HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22. Arterioscler Thromb Vasc Biol 2009;29:424-30.
29. Barter P, Gotto AM, LaRosa JC, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. NEJM 2007;357:1301-10. (Pubitemid 47481452)
30. Ridker PM, Genest J, Boekholdt SM, et al. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet 2010;376:333-39.